Article
MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction
20 Dec 2013
Abstract excerpt
UNLABELLED: The clinical experience with BCR-ABL tyrosine kinase inhibitors (TKI) for the treatment of chronic myelogenous leukemia (CML) provides compelling evidence for oncogene addiction. Yet, the molecular basis of oncogene addiction remains elusive. Through unbiased quantitative phosphoproteomic analyses of CML cells transiently exposed to BCR-ABL TKI, we identified persistent downregulation of growth factor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
